-
Feb. 2022
Gracell Biotechnologies dosed first patients in First-in-Human clinical trial evaluating GC012F, a dual-targeting FasTCAR-T Therapy for the treatment of B-Cell Non-Hodgkin's Lymphoma
-
Jan. 2022
Gracell Biotechnologies unveiled Innovation Center in U.S.
-
Dec. 2021
Gracell Biotechnologies was selected for addition to NASDAQ Biotechnology Index
-
Nov. 2021
Gracell Biotechnologies was granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy candidate GC012F for the treatment of multiple myeloma
-
Mar. 2021
Signs agreement with Lonza to manufacture Gracell's FasTCAR product candidates in the U.S.
-
Jan. 2021
Completes IPO and NASDAQ listing, raising $240 million in gross proceeds
-
Jan. 2021
NMPA approves IND for GC019F FasTCAR™ enabled autologous CAR-T therapy for r/r adult B-ALL
-
Jan. 2021
Suzhou manufacturing facility receives Medical Products Manufacturing Certificate from JSMPA
-
Dec. 2020
NMPA approves registrational seamless Phase 1/2 clinical trial for GC007g donor-derived allogeneic CAR-T cell therapy for r/r B-ALL
-
Dec. 2020
Reports first-in-human data at ASH 2020 on GC012F FasTCAR-enabled dual-targeting BCMA/CD19 cell therapy in patients with r/r MM
-
Oct. 2020
NMPA accepts IND application for GC019F autologous CAR-T cell therapy for adult B-ALL
-
Oct. 2020
Closes series C funding led by Wellington Management Company, OrbiMed, and Morningside Ventures, and participation from Vivo, Temasek, LAV, Kington Capital, and Chengdu Miaoji
-
Aug. 2020
Suzhou GMP manufacturing facility opens
-
Apr. 2020
Reports data on first-in-human clinical trial of off-the-shelf TruUCAR-enabled GC027 in r/r T-ALL at AACR 2020
-
Apr. 2020
NMPA approves IND application for GC007g donor-derived CAR-T cell therapy for CD19 positive r/r B-ALL
-
Feb. 2019
Closes series B funding from Temasek, OrbiMed, Lilly Asia Ventures, Kington Capital, and Chengdu Miaoji
-
Oct. 2017
Shanghai R&D facility opens
-
May. 2017
Gracell Biotechnologies was founded by Dr. William Wei Cao and co-founding team